feb 11, 2019: 3:30 p.m. - 4:30 p.m.
A growing number of biopharma companies have responded to the emerging medical consensus that many of the individual ailments experienced by older people have underlying, connective biological causes. These companies are developing drugs in areas such as neurodegeneration, macular degeneration, arthritis, and similar highly prevalent diseases by pursuing novel mechanisms versus existing treatments. This session will discuss the frontier of science in extending the years of healthy aging and in which indications patients might first see progressive new therapies in clinical trials.
Moderator: Susan Peschin, MHS, President and Chief Executive Officer, Alliance for Aging Research